Abstract
We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 924-928 |
| Number of pages | 5 |
| Journal | AIDS (London, England) |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Mar 2010 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
Fingerprint Dive into the research topics of 'Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience'. Together they form a unique fingerprint.
Cite this
Nozza, S., Galli, L., Visco, F., Soria, A., Canducci, F., Salpietro, S., Gianotti, N., Bigoloni, A., Torre, L. D., Tambussi, G., Lazzarin, A., & Castagna, A. (2010). Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS (London, England), 24(6), 924-928. https://doi.org/10.1097/QAD.0b013e3283372d76